How does tizanidine work. Tizanidine: Mechanism of Action, Uses, and Clinical Efficacy

28.07.202302.07.2023 by alexxlab

How does tizanidine work. What are the FDA-approved and off-label uses of tizanidine. What do clinical studies reveal about tizanidine’s efficacy compared to other muscle relaxants. How does tizanidine affect spasticity and muscle tone.

Содержание

Understanding Tizanidine: A Centrally Acting Alpha-2 Agonist

Tizanidine is a centrally acting alpha-2 receptor agonist widely used as an anti-spastic agent for various medical conditions. Its primary mechanism of action involves inhibiting the release of excitatory amino acids like glutamate and aspartate from spinal interneurons. This inhibition enhances the presynaptic inhibition of motor neurons, ultimately reducing the facilitation of spinal motor neurons.

The drug’s effects extend beyond its primary action on spasticity. Tizanidine also demonstrates anti-nociceptive and anti-convulsant activities through alpha-2 receptor-mediated inhibition of interneuronal activity. Additionally, it reduces spasm frequency and clonus, making it a versatile option for managing various neurological conditions.

Key Mechanisms of Tizanidine

Inhibition of excitatory amino acid release
Enhancement of presynaptic inhibition of motor neurons
Reduction of spinal motor neuron facilitation
Anti-nociceptive and anti-convulsant effects
Reduction of spasm frequency and clonus

FDA-Approved Indications for Tizanidine Use

The U.S. Food and Drug Administration (FDA) has approved tizanidine for managing spasticity associated with several neurological conditions. These approved indications highlight the drug’s efficacy in addressing muscle tone abnormalities across a range of disorders.

FDA-Approved Conditions for Tizanidine

Multiple sclerosis
Spinal cord injury
Stroke
Amyotrophic lateral sclerosis (ALS)
Traumatic brain injury

How effective is tizanidine in managing spasticity caused by these conditions. Clinical studies have demonstrated significant efficacy in reducing spasticity, particularly in patients with severe symptoms. The drug’s ability to target multiple aspects of muscle tone regulation makes it a valuable option for patients experiencing debilitating spasticity.

Exploring Off-Label Uses of Tizanidine

Beyond its FDA-approved indications, tizanidine has found utility in managing various other conditions. These off-label uses leverage the drug’s muscle relaxant and pain-modulating properties to address a broader range of symptoms.

Common Off-Label Applications

Chronic neck and lower back pain
Rebound headaches due to analgesic withdrawal
Chronic migraine headaches
Refractory insomnia in spastic quadriplegic patients
Regional musculoskeletal pain syndromes

Can tizanidine effectively manage these off-label conditions. While more research is needed to fully establish its efficacy in these areas, preliminary studies and clinical experience suggest that tizanidine may offer benefits for patients with these conditions, particularly when conventional treatments have proven inadequate.

Clinical Studies: Tizanidine vs. Other Muscle Relaxants

Numerous clinical studies have compared tizanidine to other commonly used muscle relaxants, such as baclofen and diazepam. These comparisons provide valuable insights into the relative efficacy and tolerability of tizanidine in managing spasticity and related symptoms.

Key Findings from Comparative Studies

Efficacy in spasticity reduction: Studies show no significant differences in efficacy between tizanidine, baclofen, and diazepam in reducing spasticity, as measured by the Ashworth score.
Improvement in muscle strength: Tizanidine demonstrated the most significant improvement in muscle strength compared to baclofen and diazepam in patients with multiple sclerosis or cerebrovascular lesions.
Tolerability: Tizanidine generally exhibits better tolerability than diazepam and baclofen, with fewer reported adverse effects.
Sedation: Diazepam was associated with more sedation compared to tizanidine and other muscle relaxants.
Global tolerability: When considering overall treatment tolerability, tizanidine was favored over baclofen and diazepam in some studies.

Do these comparative studies suggest a clear advantage for tizanidine. While the drug shows comparable efficacy to other muscle relaxants, its improved tolerability profile and potential for fewer adverse effects may make it a preferred option for many patients, particularly those sensitive to the sedative effects of other medications.

Tizanidine in Spasticity Management: Efficacy and Patient Selection

Placebo-controlled studies have confirmed the significant efficacy of tizanidine in reducing spasticity, particularly in patients with spinal cord-induced spasticity. The literature suggests that patients with severe spasticity are more likely to benefit from tizanidine therapy, highlighting the importance of appropriate patient selection.

Factors Influencing Tizanidine Efficacy

Severity of spasticity
Underlying cause of spasticity
Patient’s overall health status
Concurrent medications and potential interactions
Individual response to alpha-2 agonists

How can healthcare providers optimize tizanidine therapy for spasticity management. Tailoring the treatment approach to each patient’s specific needs and carefully monitoring their response to therapy is crucial. Regular assessments of spasticity levels, functional improvements, and potential adverse effects can help guide dosage adjustments and ensure optimal outcomes.

Tizanidine in Pain Management: Beyond Spasticity

While primarily known for its anti-spastic properties, tizanidine has shown promise in managing various pain conditions. Its alpha-2 agonist activity contributes to its analgesic effects, making it a valuable option for patients with chronic pain syndromes.

Pain Conditions Potentially Responsive to Tizanidine

Chronic neck and lower back pain with a myofascial component
Neuropathic pain, including trigeminal neuralgia
Migraine headaches
Regional musculoskeletal pain syndromes
Perioperative pain management

Can tizanidine effectively replace traditional pain medications in these conditions. While tizanidine may not completely replace conventional analgesics, it can serve as a valuable adjunct to pain management strategies. Its unique mechanism of action may provide relief for patients who have not responded adequately to other treatments or who cannot tolerate the side effects of traditional pain medications.

Tizanidine in Neurological Disorders: Expanding Applications

Beyond its primary use in spasticity management, tizanidine has found applications in various neurological disorders. Its ability to modulate neurotransmitter release and influence central nervous system activity makes it a versatile option for addressing multiple symptoms associated with neurological conditions.

Neurological Applications of Tizanidine

Multiple sclerosis: Managing spasticity and associated pain
Spinal cord injury: Reducing muscle tone and improving functional outcomes
Stroke rehabilitation: Facilitating motor recovery and managing post-stroke spasticity
Traumatic brain injury: Addressing spasticity and associated complications
Amyotrophic lateral sclerosis: Symptom management and quality of life improvement

How does tizanidine compare to other treatments for these neurological conditions. While tizanidine may not be the primary treatment for these disorders, it can play a crucial role in symptom management and improving patient quality of life. Its use should be considered as part of a comprehensive treatment approach, tailored to each patient’s specific needs and symptoms.

Safety Profile and Adverse Effects of Tizanidine

Understanding the safety profile and potential adverse effects of tizanidine is crucial for healthcare providers and patients alike. While generally well-tolerated, tizanidine can cause several side effects that require careful monitoring and management.

Common Adverse Effects

Drowsiness and sedation
Dizziness
Dry mouth
Weakness
Hypotension

Less Common but Serious Adverse Effects

Liver toxicity
Hallucinations
Bradycardia
Severe hypotension

How can healthcare providers mitigate the risk of adverse effects associated with tizanidine use. Careful patient selection, dosage titration, and regular monitoring are essential. Patients should be educated about potential side effects and instructed to report any unusual symptoms promptly. Additionally, avoiding concomitant use of CYP1A2 inhibitors and monitoring liver function can help prevent serious complications.

Tizanidine in Special Populations: Considerations and Precautions

The use of tizanidine in special populations, such as elderly patients, those with renal or hepatic impairment, and pregnant or breastfeeding women, requires careful consideration. Understanding the pharmacokinetics and potential risks in these groups is essential for safe and effective tizanidine use.

Special Populations and Considerations

Elderly patients: Increased risk of adverse effects, may require lower starting doses
Renal impairment: Dose adjustment may be necessary due to decreased clearance
Hepatic impairment: Contraindicated in severe liver disease, use with caution in mild to moderate impairment
Pregnancy: Limited data available, use only if benefits outweigh potential risks
Breastfeeding: Tizanidine is excreted in breast milk, caution advised

How should healthcare providers approach tizanidine use in these special populations. Individualized treatment plans, close monitoring, and careful dose titration are crucial. Consulting with specialists, such as geriatricians, nephrologists, or hepatologists, may be necessary to optimize tizanidine therapy in complex cases.

Tizanidine in Combination Therapy: Synergies and Interactions

Tizanidine is often used in combination with other medications to manage complex neurological conditions or pain syndromes. Understanding potential drug interactions and synergistic effects is crucial for optimizing treatment outcomes and minimizing risks.

Common Combination Therapies

Tizanidine with botulinum toxin-A for localized spasticity
Combination with non-steroidal anti-inflammatory drugs (NSAIDs) for pain management
Use alongside physical therapy and rehabilitation programs
Adjunct to antiepileptic drugs in certain pain conditions

Important Drug Interactions

CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): Can significantly increase tizanidine levels
Alpha-2 agonists (e.g., clonidine): May potentiate hypotensive effects
CNS depressants: Can enhance sedative effects
Oral contraceptives: May increase tizanidine bioavailability

How can healthcare providers optimize combination therapy involving tizanidine. Careful medication reconciliation, awareness of potential interactions, and close monitoring of patient response are essential. Adjusting dosages of tizanidine or concomitant medications may be necessary to achieve the desired therapeutic effect while minimizing adverse reactions.

Future Directions: Tizanidine Research and Potential Applications

As our understanding of tizanidine’s mechanisms and effects continues to grow, researchers are exploring new potential applications and refining its use in existing indications. Ongoing studies aim to expand the therapeutic utility of tizanidine and improve patient outcomes across various medical conditions.

Areas of Active Research

Tizanidine in neuropathic pain management
Role in opioid withdrawal and addiction treatment
Potential applications in movement disorders
Optimizing dosing strategies for improved efficacy and tolerability
Long-term safety and efficacy in chronic use

What potential breakthroughs might emerge from ongoing tizanidine research. While it’s difficult to predict specific outcomes, continued investigation into tizanidine’s mechanisms and effects may lead to novel therapeutic applications, improved formulations, or combination therapies that enhance its efficacy and safety profile. As our understanding of neurological disorders and pain syndromes evolves, tizanidine may play an increasingly important role in comprehensive treatment strategies.

In conclusion, tizanidine represents a valuable tool in the management of spasticity, pain, and various neurological conditions. Its unique mechanism of action, favorable tolerability profile, and versatility make it an important option for healthcare providers treating patients with complex neurological and musculoskeletal disorders. As research continues to uncover new applications and refine existing uses, tizanidine is likely to remain a significant player in the therapeutic landscape for years to come.

Tizanidine – StatPearls – NCBI Bookshelf

Continuing Education Activity

Tizanidine is an FDA-approved drug for managing spasticity. It is a centrally acting alpha-2 receptor agonist. Tizanidine effectively works with spasticity caused by multiple sclerosis, an acquired brain injury, or a spinal cord injury. It has also been shown to be clinically effective in managing patients suffering from chronic neck and lumbosacral neuralgia with a myofascial component to their pain and regional musculoskeletal pain syndromes. It is also prescribed off-label for migraine headaches, insomnia, and as an anticonvulsant. Tizanidine can also be applied as part of a detoxification therapy regimen in patients exhibiting analgesic rebound headaches to assist with analgesic withdrawal. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, toxicity, and monitoring, of tizanidine so providers can direct patient therapy as part of the inter-professional team.

Objectives:

Explain the mechanism of action of tizanidine.
Identify the clinical indications for tizanidine use.
Review the adverse reaction profile of tizanidine.
Summarize inter-professional team strategies for improving care, coordination, and communication for improving patient outcomes related to tizanidine therapy.

Access free multiple choice questions on this topic.

Indications

Tizanidine is a centrally acting alpha-2 agonist. Tizanidine is widely used as an anti-spastic agent for multiple medical conditions.

FDA-approved Indication

Tizanidine is indicated for spasticity management due to multiple sclerosis, spinal cord injury, stroke, amyotrophic lateral sclerosis, and traumatic brain injury.[1][2][3]

Off-label Use

Chronic neck and lower back pain[4]
Rebound headaches due to analgesic withdrawal[5]
Chronic migraine headaches[6]
Refractory insomnia in spastic quadriplegic patients[7]
Regional musculoskeletal pain syndromes[4]

Clinical Studies

Placebo-controlled studies confirm the significant efficacy of tizanidine in reducing spasticity in patients with spinal cord-induced spasticity. Literature suggests that patients with severe spasticity are more likely to benefit from the therapy. Drug comparison studies have shown no differences in the efficacy of tizanidine compared with baclofen or diazepam. The tizanidine treatment group did not report increased weakness compared to the controls. Furthermore, patients given tizanidine experienced fewer adverse effects than those using controlled substances.[8]
Studies exhibit that tizanidine, baclofen, and diazepam effectively decreased excessive muscle tone in patients with multiple sclerosis or cerebrovascular lesions. Muscle strength improved in all three treatment groups, but the improvement was most significant with tizanidine. Shakespeare et al. also reported similar findings showing no differences in efficacy between tizanidine, baclofen, and dantrolene compared to diazepam. However, diazepam was associated with more sedation.[9]
Another study by Lataste et al. showed no significant differences between tizanidine and baclofen or diazepam for muscle tone, muscle spasms, clonus, muscle strength, or overall anti-spastic effect. However, tizanidine tolerance is slightly better than diazepam and baclofen.[10]
Groves et al. report no significant differences between tizanidine, baclofen, or diazepam for spasticity by Ashworth score. However, applying global tolerability to treatment favored tizanidine compared to baclofen and diazepam.[11]
Animal studies have shown that tizanidine provides benefits in the perioperative period and the management of neuropathic pain, such as trigeminal neuralgia, similar to the effects of clonidine under similar circumstances.
A recent study indicates that tizanidine and other alpha-2 agonists can be used for medically supervised opioid withdrawal.[12]
The American Academy of Neurology guidelines reports that tizanidine should be used for generalized spasticity in cerebral palsy, for segmental/localized spasticity treatment with botulinum toxin-A is more effective.[13]

Mechanism of Action

Tizanidine is an imidazoline derivative and a centrally acting alpha-2 receptor agonist. Tizanidine inhibits the release of excitatory amino acids like glutamate and aspartate from spinal interneurons. Consequently, tizanidine enhances the presynaptic inhibition of motor neurons. Tizanidine has significant action on spinal polysynaptic pathways.[14]

The overall effect of these actions is to reduce the facilitation of spinal motor neurons. Similarly, alpha-2 receptor-mediated inhibition of inter-neuronal activity appears to underlie tizanidine’s additional anti-nociceptive and anti-convulsant activities. Spasm frequency and clonus are also reduced by tizanidine.[15]

Tizanidine also has an affinity for the alpha-1 receptors but to a lesser degree, which may explain its mild and transitory effect on the cardiovascular system compared to clonidine despite their structural and biochemical similarity.[16]

Pharmacokinetics

Absorption: Tizanidine has a significant, first-pass hepatic metabolism with an oral bioavailability of 20% to 34%. Tizanidine attains the steady-state concentration within 24 to 48 hours after administration. There is no noticeable change in its pharmacokinetic behavior with repeated intake.[17]

Distribution: Tizanidine has extensive tissue distribution; the volume of distribution is 2.4 L/kg. The plasma protein binding of tizanidine is approximately 30%.

Metabolism: Tizanidine is metabolized extensively in the liver by cytochrome P450-1A2 to inactive metabolites.

Excretion: Tizanidine has an elimination half-life of 2.5 hours, follows linear pharmacokinetics, and is excreted 60% through urine and 20% through feces.[18]

Administration

Tizanidine is administrated orally as 2 mg, 4 mg, and 6 mg capsules or as 2 mg and 4 mg tablets. Dosage starts with 2 mg orally and may repeat every 6 to 8 hours as needed. The dosage may gradually increase by 2 to 4 mg per dose for 1 to 4 days in between until there is a noticeably significant reduction of spasticity. Maximum dosing is three doses every 24 hours, up to 36 mg daily.

If tizanidine is used for more than nine weeks or given in high doses ranging from 20 mg to 36 mg daily, taper the dose gradually. The recommendation is to taper the dose to 2 to 4 mg daily to reduce the risk of tachycardia, rebound hypertension, and increased spasticity.[19]

The patient may open the capsule and sprinkle the contents into food. Patients can take tizanidine with food or on an empty stomach. It is important to note that the extent of absorption is greater when taken with food. The tablet and capsule dosage forms are not bioequivalent when administered with food. Hence, the clinician should counsel the patient to take tizanidine with or without food but be consistent to avoid fluctuations in concentration.[20] It is also important to recognize that smoking decreases tizanidine’s plasma concentration and exposure(AUC).[21]

Use in Specific Patient Population

Patients with Hepatic Impairment: The consequence of Hepatic impairment on the pharmacokinetics of tizanidine has not been evaluated. However, tizanidine is extensively metabolized by the liver; therefore, hepatic impairment would significantly influence the pharmacokinetics of tizanidine. Therefore, tizanidine should be avoided or used with extreme caution in patients with hepatic impairment.

Patients with Renal Impairment: Tizanidine should be used cautiously in patients with renal impairment (creatinine clearance < 25 mL/min), as clearance is decreased by more than 50%. Start with a low dose, evaluate the response to therapy, and if a higher dose is needed, the dose can be increased rather than increasing the frequency of administration. The clinician should monitor the patient closely for adverse drug reactions such as dry mouth, drowsiness, asthenia, and dizziness as indicators of toxicity.

Pregnancy Considerations: The use of tizanidine in managing spinal cord injury during pregnancy has been described in case reports.[22] However, it is important to note that tizanidine is a former FDA pregnancy category-C and should be used only if indicated after careful risk-benefit evaluation.

Breastfeeding Considerations: Tizanidine is a lipid-soluble drug; hypothetically, it may be present in breast milk; its use during lactation is not advised.

Adverse Effects

Tizanidine is generally well-tolerated. However, reports exist of potential adverse effects on several organs, such as cutaneous, gastrointestinal, neurologic, cardiovascular, endocrine, and respiratory systems.

Common Adverse Drug Reactions

Drowsiness
Blurred vision
Asthenia
Constipation
Dyskinesia
Nervousness
Hallucination
Rhinitis
Xerostomia[15]
Dizziness[23]

Severe Adverse Drug Reactions

Severe hepatotoxicity and liver failure[24]
Anaphylaxis
Exfoliative dermatitis
Severe hypotension[25]
QT interval prolongation[26]
Severe bradycardia[27]
Stevens-Johnson syndrome[28]
Refractory hypokalemia and potassium wasting nephropathy[29]

Withdrawal Symptoms

Tachycardia
Rebound hypertension
Increased spasticity
Withdrawal symptoms are more likely to occur when discontinuing the drug abruptly. [19]

Drug Interactions

Concomitant use of tizanidine with fluvoxamine or ciprofloxacin is contraindicated due to significant hypotension and increased psychomotor impairment.[30] A recent retrospective analysis of the WHO pharmacovigilance database identified severe cardiac and nervous system adverse drug reactions. The study concluded that the concomitant use of ciprofloxacin with tizanidine should be avoided.[31]
Because of potential drug interactions, using tizanidine with other CYP1A2 inhibitors such as oral contraceptives containing Ethinyl estradiol and gestodene, dronedarone, pimozide, saquinavir, cimetidine, famotidine, acyclovir, and ticlopidine should be avoided due to decreased clearance of tizanidine.[32]
If tizanidine is clinically necessary, therapy should be initiated with 2 mg and increased to 2 to 4 mg daily based on patient response to therapy.
Adverse reactions such as hypotension, bradycardia, or excessive sedation require gradual dose reduction or stopping therapy.
Tizanidine should be used cautiously in patients on other alpha-2 adrenergic receptor agonists.
Patients should avoid alcohol and benzodiazepines with tizanidine as it can lead to excessive sedation and myocardial toxicity in rare instances.[33]
Vemurafenib used in BRAF mutation-positive malignancy is an inhibitor of CYP1A2 and can increase plasma concentration of tizanidine, leading to potential toxicity.[34]

Contraindications

Hypersensitivity to tizanidine or its ingredients is a contraindication to the use of tizanidine.
Tizanidine use requires caution in patients with hepatic impairment. Review articles on tizanidine report cases of severe hepatotoxicity, acute liver failure, and death.[24]
According to product labeling, tizanidine use requires caution in patients with renal impairment (creatinine clearance < 25 mL/min). In such patients, decrease the dose. If high doses are necessary, increase the individual dosage rather than the dosage frequency.

Monitoring

Creatinine and liver function tests require measurement at baseline, then one month after the maintenance dose is achieved. Periodically monitor liver function tests in patients managed with tizanidine chronically and in higher doses.[24]
Monitor blood pressure and heart rate before increasing the dosage because of the risk of severe hypotension associated with the higher dose.[25]
Monitor the level of spasticity by Ashworth and modified Ashworth Scales.[35]
In patients with multiple sclerosis, monitor spasticity using MS Spasticity Scale(MSSS-88).[36]

Toxicity

The maximum recommended dose of tizanidine is 36 mg/day.[37]
In the retrospective review, which included 45 patients, the mean dose ingested was 72 mg (Above the maximum recommended dose).

Clinical Features

Lethargy
Bradycardia
Hypotension
Agitation
Confusion
Vomiting
Drowsiness
Coma

Management

There is no antidote for tizanidine toxicity.
Tizanidine overdose management is by close monitoring of airways, administration of intravenous fluid, and vasopressors as necessary.[25]
The pediatric case report described an overdose of tizanidine in spastic quadriplegia and toxicity presented with multiple organ dysfunction in the absence of sepsis.[37]
A recent case report described the altered mental status and hemodynamic instability due to tizanidine overdose, and naloxone 10 mg IV administration improved Richmond Agitation-Sedation Scale(RASS).[38] The study concluded that naloxone could be used in tizanidine overdose in emergency settings; however, naloxone does not reverse the hemodynamic parameters.[39]

Enhancing Healthcare Team Outcomes

Tizanidine is a centrally acting alpha-2 agonist prescribed to manage spasticity caused by multiple sclerosis, stroke, and spinal cord injury. Tizanidine is also used off-label for managing patients suffering from chronic neck and back pain and chronic migraines. However, this drug can cause hypotension, bradycardia, and hepatotoxicity. Hence all healthcare providers need to understand indications, mechanisms, adverse effects, and their management.

The clinician prescribes tizanidine for appropriate indication and should assess liver function tests at baseline and one month. In addition, the neurologist should evaluate the improvement in spasticity related to neurological disorders such as multiple sclerosis, stroke, and spinal cord injury. Nurses can check compliance, monitor for adverse events, and counsel patients for adherence to therapy. The pharmacist should verify the dosing regimen, perform medication reconciliation for drug interactions, and counsel the patient on adverse drug reactions. In addition, patients need to be warned not to combine it with antihypertensive medications. In the overdose of tizanidine, triage nurses should admit the patient, and the emergency department physicians should monitor blood pressure and heart rate and obtain 12 lead EKG. Additionally, a liver function test is required to assess for hepatotoxicity. The critical care physician should manage severe overdose, which requires vasopressors and fluids during the ICU stay.

As depicted above, there are multiple healthcare providers, including clinicians (MDs, DOs, NPs, PAs), specialists, pharmacists, and nurses, involved in taking care of the patient. Tizanidine can be an effective therapeutic agent, but it requires the entire interprofessional healthcare team to collaborate and communicate for therapy to be successful. In addition, a recent study noted that interprofessional care between clinicians, neurologists, pharmacists, nurses, physical therapists, speech and language therapists, and occupational therapists is crucial for providing patient-centered care in patients with multiple sclerosis.[40] [Level 5]

Review Questions

Access free multiple choice questions on this topic.
Comment on this article.

References

1.: Kamen L, Henney HR, Runyan JD. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin. 2008 Feb;24(2):425-39. [PubMed: 18167175]
2.: Dorst J, Ludolph AC, Huebers A. Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis. Ther Adv Neurol Disord. 2018;11:1756285617734734. [PMC free article: PMC5784546] [PubMed: 29399045]
3.: Chang E, Ghosh N, Yanni D, Lee S, Alexandru D, Mozaffar T. A Review of Spasticity Treatments: Pharmacological and Interventional Approaches. Crit Rev Phys Rehabil Med. 2013;25(1-2):11-22. [PMC free article: PMC4349402] [PubMed: 25750484]
4.: Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother. 2008 Aug;9(12):2209-15. [PubMed: 18671474]
5.: Smith TR. Low-dose tizanidine with nonsteroidal anti-inflammatory drugs for detoxification from analgesic rebound headache. Headache. 2002 Mar;42(3):175-7. [PubMed: 11903539]
6.: Yancey JR, Sheridan R, Koren KG. Chronic daily headache: diagnosis and management. Am Fam Physician. 2014 Apr 15;89(8):642-8. [PubMed: 24784123]
7.: Tanaka H, Fukuda I, Miyamoto A, Oka R, Cho K, Fujieda K. [Effects of tizanidine for refractory sleep disturbance in disabled children with spastic quadriplegia]. No To Hattatsu. 2004 Nov;36(6):455-60. [PubMed: 15560387]
8.: Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology. 1994 Nov;44(11 Suppl 9):S60-8; discussion S68-9. [PubMed: 7970013]
9.: Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2001;(4):CD001332. [PubMed: 11687107]
10.: Lataste X, Emre M, Davis C, Groves L. Comparative profile of tizanidine in the management of spasticity. Neurology. 1994 Nov;44(11 Suppl 9):S53-9. [PubMed: 7970011]
11.: Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther. 1998 Jul-Aug;15(4):241-51. [PubMed: 10186943]
12.: Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet. 2020 Jun 20;395(10241):1938-1948. [PMC free article: PMC7385662] [PubMed: 32563380]
13.: Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Delgado MR, Hirtz D, Aisen M, Ashwal S, Fehlings DL, McLaughlin J, Morrison LA, Shrader MW, Tilton A, Vargus-Adams J. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2010 Jan 26;74(4):336-43. [PMC free article: PMC3122302] [PubMed: 20101040]
14.: Fuchigami T, Kakinohana O, Hefferan MP, Lukacova N, Marsala S, Platoshyn O, Sugahara K, Yaksh TL, Marsala M. Potent suppression of stretch reflex activity after systemic or spinal delivery of tizanidine in rats with spinal ischemia-induced chronic spastic paraplegia. Neuroscience. 2011 Oct 27;194:160-9. [PMC free article: PMC3192017] [PubMed: 21871540]
15.: Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52. [PubMed: 9074844]
16.: Coward DM. Tizanidine: neuropharmacology and mechanism of action. Neurology. 1994 Nov;44(11 Suppl 9):S6-10; discussion S10-1. [PubMed: 7970012]
17.: Tse FL, Jaffe JM, Bhuta S. Pharmacokinetics of orally administered tizanidine in healthy volunteers. Fundam Clin Pharmacol. 1987;1(6):479-88. [PubMed: 3447935]
18.: Granfors MT, Backman JT, Laitila J, Neuvonen PJ. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol. 2004 Mar;57(3):349-53. [PMC free article: PMC1884447] [PubMed: 14998432]
19.: Suárez-Lledó A, Padullés A, Lozano T, Cobo-Sacristán S, Colls M, Jódar R. Management of Tizanidine Withdrawal Syndrome: A Case Report. Clin Med Insights Case Rep. 2018;11:1179547618758022. [PMC free article: PMC5815413] [PubMed: 29467587]
20.: Henney HR, Shah J. Relative bioavailability of tizanidine 4-mg capsule and tablet formulations after a standardized high-fat meal: a single-dose, randomized, open-label, crossover study in healthy subjects. Clin Ther. 2007 Apr;29(4):661-9. [PubMed: 17617289]
21.: Al-Ghazawi M, Alzoubi M, Faidi B. Pharmacokinetic comparison of two 4 mg tablet formulations of tizanidine. Int J Clin Pharmacol Ther. 2013 Mar;51(3):255-62. [PubMed: 23380428]
22.: Qureshi AZ, Ullah S, AlSaleh AJ, Ullah R. Spinal cord injury during the second trimester of pregnancy. Spinal Cord Ser Cases. 2017;3:17052. [PMC free article: PMC5550924] [PubMed: 28808585]
23.: Saper JR, Lake AE, Cantrell DT, Winner PK, White JR. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 2002 Jun;42(6):470-82. [PubMed: 12167135]
24.: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): Jan 30, 2017. Tizanidine. [PubMed: 31643379]
25.: Spiller HA, Bosse GM, Adamson LA. Retrospective review of Tizanidine (Zanaflex) overdose. J Toxicol Clin Toxicol. 2004;42(5):593-6. [PubMed: 15462150]
26.: Kaddar N, Vigneault P, Pilote S, Patoine D, Simard C, Drolet B. Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr. J Cardiovasc Pharmacol Ther. 2012 Mar;17(1):102-9. [PubMed: 21317414]
27.: Kitabata Y, Orita H, Kamimura M, Shiizaki K, Narukawa N, Abe T, Kobata H, Akizawa T. Symptomatic bradycardia probably due to tizanidine hydrochloride in a chronic hemodialysis patient. Ther Apher Dial. 2005 Feb;9(1):74-7. [PubMed: 15828911]
28.: Ishiguro A, Shibata T, Yanagishita T, Takama H, Uchida R, Ohshima Y, Watanabe D. A case of drug-induced Stevens-Johnson syndrome-like eruption predominating in mucosa: A case report. Clin Case Rep. 2020 Aug;8(8):1379-1381. [PMC free article: PMC7455421] [PubMed: 32884758]
29.: Brucculeri MJ, Garcia J. Potassium wasting nephropathy in the setting of tizanidine overdose: a case report. J Med Case Rep. 2021 May 01;15(1):250. [PMC free article: PMC8088014] [PubMed: 33931107]
30.: Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther. 2004 Dec;76(6):598-606. [PubMed: 15592331]
31.: Rudolph A, Dahmke H, Kupferschmidt H, Burden A, Weiler S. Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database. Eur J Clin Pharmacol. 2021 Jun;77(6):895-902. [PMC free article: PMC8128801] [PubMed: 33404754]
32.: Chaugai S, Dickson AL, Shuey MM, Feng Q, Barker KA, Wei WQ, Luther JM, Stein CM, Chung CP. Co-Prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine-Associated Hypotension: A Retrospective Cohort Study. Clin Pharmacol Ther. 2019 Mar;105(3):703-709. [PMC free article: PMC6379114] [PubMed: 30223305]
33.: Amino M, Yoshioka K, Ikari Y, Inokuchi S. Long-term myocardial toxicity in a patient with tizanidine and etizolam overdose. J Cardiol Cases. 2016 Mar;13(3):78-81. [PMC free article: PMC6280692] [PubMed: 30546611]
34.: Zhang W, McIntyre C, Riehl T, Forbes H, Bertran E, Choi HJ, Lee DH, Lee J. Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAF^V600 Mutation-Positive Malignancies. Clin Pharmacol Drug Dev. 2020 Jul;9(5):651-658. [PubMed: 32311241]
35.: Meseguer-Henarejos AB, Sánchez-Meca J, López-Pina JA, Carles-Hernández R. Inter- and intra-rater reliability of the Modified Ashworth Scale: a systematic review and meta-analysis. Eur J Phys Rehabil Med. 2018 Aug;54(4):576-590. [PubMed: 28901119]
36.: Hui D, Argáez C. Onabotulinum Toxin A (Botox) for Spasticity Associated With Multiple Sclerosis [Internet]. Canadian Agency for Drugs and Technologies in Health; Ottawa (ON): Mar, 2021. [PubMed: 34260163]
37.: Vila J, Morgenstern A, Vendrell L, Ortega J, Danés I. Liver, Renal, and Cardiovascular Failure After Unintentional Overdose of Tizanidine in a 2-Year-Old Child. J Pediatr Pharmacol Ther. 2021;26(6):643-646. [PMC free article: PMC8372862] [PubMed: 34421416]
38.: Kerson AG, DeMaria R, Mauer E, Joyce C, Gerber LM, Greenwald BM, Silver G, Traube C. Validity of the Richmond Agitation-Sedation Scale (RASS) in critically ill children. J Intensive Care. 2016;4:65. [PMC free article: PMC5080705] [PubMed: 27800163]
39.: Adams A, Copley C. High dose naloxone for acute tizanidine overdose in the emergency department: a case report. Clin Toxicol (Phila). 2021 Aug;59(8):764-765. [PubMed: 33403870]
40.: Schmid F, Rogan S, Glässel A. A Swiss Health Care Professionals’ Perspective on the Meaning of Interprofessional Collaboration in Health Care of People with MS-A Focus Group Study. Int J Environ Res Public Health. 2021 Jun 17;18(12) [PMC free article: PMC8297392] [PubMed: 34204475]

: Disclosure: Shirin Ghanavatian declares no relevant financial relationships with ineligible companies.
: Disclosure: Armen Derian declares no relevant financial relationships with ineligible companies.